BioAge Labs, Inc. has entered into a multi-year research collaboration with Novartis to explore therapeutic targets for metabolic diseases associated with aging.

The collaboration is designed to investigate the biological mechanisms underlying aging-related diseases and the positive effects of physical exercise.

Michaela Kneissel from Novartis expressed enthusiasm about the potential of combining BioAge's extensive data with Novartis' expertise to uncover novel therapeutic targets.

BioAge's proprietary discovery platform utilizes longitudinal human aging data, allowing for advanced analytics that identify key determinants of a healthy lifespan.

Kristen Fortney, CEO of BioAge, highlighted that their platform effectively leverages extensive human longevity data to pinpoint promising therapeutic pathways.

BioAge's lead candidate, azelaprag, has demonstrated potential in promoting metabolism and preventing muscle atrophy during a Phase 1b clinical trial.

In addition to their collaboration with Novartis, BioAge is developing small molecule NLRP3 inhibitors aimed at treating neuroinflammation-driven diseases, focusing on metabolic aging pathways.

As part of the agreement, BioAge will receive up to $20 million in upfront payments and research funding from Novartis, with additional potential milestones totaling up to $530 million.

Both BioAge and Novartis retain the rights to advance any novel targets discovered during the collaboration and are eligible for success milestones and royalties.

The announcement includes a disclaimer about forward-looking statements and potential risks that may impact BioAge's development and commercial prospects.